INS NYC 2024 Program

Poster	Poster Session 09 Program Schedule 02/16/2024 03:30 pm - 04:45 pm Room: Majestic Complex (Posters 61-120) Poster Session 09: Epilepsy \| Oncology \| MS \| Infectious Disease Final Abstract #101 A Novel Touch-Panel Screening Battery for Detecting HIV-Related Neurocognitive Impairment Maiko Sakamoto, Faculty of Medicine, Saga University, Saga, Japan Jundai Tsurumi, Graduate School of Engineering and Management, Suwa University of Science, Suwa, Japan Aya Nakao, Ehime University Hospital, Toon, Japan Jun Yamanouchi, Ehime University Hospital, Toon, Japan Hirotomo Nakata, Kumamoto University Hospital, Kumamoto, Japan Rumi Minami, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan Shuzo Matsushita, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan Tania Giovannetti, Department of Psychology and Neuroscience, Temple University, Philadelphia, United States Takehiko Yamaguchi, Faculty of Engineering, Department of Applied Engineering, Suwa University of Science, Suwa, Japan Category: Infectious Disease (HIV/COVID/Hepatitis/Viruses) Keyword 1: HIV/AIDS Keyword 2: test development Objective: Despite the average age of HIV-infected individuals being in their mid-40s, reports indicate cognitive decline and diagnoses of HIV-associated neurocognitive disorders (HAND). Many of these individuals live alone, underscoring the importance of assessing their neurocognitive and everyday functioning during hospital visits to identify mild cognitive impairment. However, this provides challenges for Japanese clinicians due to a shortage of clinical psychologists and neuropsychologists to conduct evaluations. The current study aimed to 1) develop a touch-panel HAND screening battery and 2) evaluate its ability to differentiate between healthy adults and HIV-infected individuals, as well as between HIV-infected individuals with no-HAND and those with HAND. Participants and Methods: Forty-one HIV-infected men (age: 47.1 ±6.99 years, education: 13.8±2.17 years) and 45 healthy men (age: 44.2 ±7.60 years, education: 14.5±2.28 years) completed the touch-panel HAND screening battery, assessing six neuropsychological domains (learning, memory, attention, executive function, information processing speed, and motor function) via seven subtests. Everyday function and depression also were evaluated. Of 41 HIV-infected participants, 15 were diagnosed with HAND (age: 46.3 ±6.53 years, education: 13.8±2.34 years) based on performance on a comprehensive clinical examination that included paper-and-pencil neuropsychological tests. Results: Wilcoxon tests revealed significant differences between the HIV+ group and the healthy group in short-term memory (c²= 7.586, p= 0.006), long-term memory (c²= 6.974, p= 0.008), digit symbol (c²= 5.729, p= 0.017), Trail Making Test (TMT)–B (c²= 8.770, p= 0.003), Stroop interference (c²= 3.861, p= 0.049), and depression scale (c²= 10.422, p= 0.001). Within the HIV+ group, individuals with HAND scored significantly lower than their healthy counterparts in short-term memory (p= 0.002), long-term memory (p= 0.018), digit symbol (p= 0.004), 2-back (p= 0.022), TMT-B (completion time: p< 0.001, errors: p= 0.018), Stroop interference (p= 0.001), and depression scale (p= 0.001). Furthermore, the short-term memory (p= 0.012), Digit symbol (p= 0.024), TMT-B (p= 0.0002), Stroop interference (p= 0.002) and depression scale (p= 0.006) effectively differentiated individuals with Asymptomatic Neurocognitive Impairment (ANI) from healthy individuals. Conclusions: Our novel, touch-panel HAND screening test can effectively detect HIV-associated cognitive impairment, including the mild form of HAND, ANI. Given that the touch-panel screening battery requires minimal administrative staff involvement, this screening test could be beneficial for Japanese hospitals and clinics that do not have enough clinical neuropsychologists to evaluate HAND.

Poster

02/16/2024
03:30 pm - 04:45 pm
Room: Majestic Complex (Posters 61-120)

Poster Session 09: Epilepsy | Oncology | MS | Infectious Disease

Final Abstract #101

A Novel Touch-Panel Screening Battery for Detecting HIV-Related Neurocognitive Impairment

Maiko Sakamoto, Faculty of Medicine, Saga University, Saga, Japan
Jundai Tsurumi, Graduate School of Engineering and Management, Suwa University of Science, Suwa, Japan
Aya Nakao, Ehime University Hospital, Toon, Japan
Jun Yamanouchi, Ehime University Hospital, Toon, Japan
Hirotomo Nakata, Kumamoto University Hospital, Kumamoto, Japan
Rumi Minami, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
Shuzo Matsushita, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan
Tania Giovannetti, Department of Psychology and Neuroscience, Temple University, Philadelphia, United States
Takehiko Yamaguchi, Faculty of Engineering, Department of Applied Engineering, Suwa University of Science, Suwa, Japan

Category: Infectious Disease (HIV/COVID/Hepatitis/Viruses)

Keyword 1: HIV/AIDS
Keyword 2: test development

Objective:

Despite the average age of HIV-infected individuals being in their mid-40s, reports indicate cognitive decline and diagnoses of HIV-associated neurocognitive disorders (HAND). Many of these individuals live alone, underscoring the importance of assessing their neurocognitive and everyday functioning during hospital visits to identify mild cognitive impairment. However, this provides challenges for Japanese clinicians due to a shortage of clinical psychologists and neuropsychologists to conduct evaluations. The current study aimed to 1) develop a touch-panel HAND screening battery and 2) evaluate its ability to differentiate between healthy adults and HIV-infected individuals, as well as between HIV-infected individuals with no-HAND and those with HAND.

Participants and Methods:

Forty-one HIV-infected men (age: 47.1 ±6.99 years, education: 13.8±2.17 years) and 45 healthy men (age: 44.2 ±7.60 years, education: 14.5±2.28 years) completed the touch-panel HAND screening battery, assessing six neuropsychological domains (learning, memory, attention, executive function, information processing speed, and motor function) via seven subtests. Everyday function and depression also were evaluated. Of 41 HIV-infected participants, 15 were diagnosed with HAND (age: 46.3 ±6.53 years, education: 13.8±2.34 years) based on performance on a comprehensive clinical examination that included paper-and-pencil neuropsychological tests.

Results:

Wilcoxon tests revealed significant differences between the HIV+ group and the healthy group in short-term memory (c²= 7.586, p= 0.006), long-term memory (c²= 6.974, p= 0.008), digit symbol (c²= 5.729, p= 0.017), Trail Making Test (TMT)–B (c²= 8.770, p= 0.003), Stroop interference (c²= 3.861, p= 0.049), and depression scale (c²= 10.422, p= 0.001). Within the HIV+ group, individuals with HAND scored significantly lower than their healthy counterparts in short-term memory (p= 0.002), long-term memory (p= 0.018), digit symbol (p= 0.004), 2-back (p= 0.022), TMT-B (completion time: p< 0.001, errors: p= 0.018), Stroop interference (p= 0.001), and depression scale (p= 0.001). Furthermore, the short-term memory (p= 0.012), Digit symbol (p= 0.024), TMT-B (p= 0.0002), Stroop interference (p= 0.002) and depression scale (p= 0.006) effectively differentiated individuals with Asymptomatic Neurocognitive Impairment (ANI) from healthy individuals.

Conclusions:

Our novel, touch-panel HAND screening test can effectively detect HIV-associated cognitive impairment, including the mild form of HAND, ANI. Given that the touch-panel screening battery requires minimal administrative staff involvement, this screening test could be beneficial for Japanese hospitals and clinics that do not have enough clinical neuropsychologists to evaluate HAND.